Loading...
LivaNova Q1 2025 Earnings Report
LivaNova reported strong first-quarter 2025 results, with significant revenue growth and improved profitability, and updated its full-year 2025 guidance.
Key Takeaways
LivaNova PLC announced robust first-quarter 2025 results, with revenue increasing by 7.4% on a reported basis and 10.4% organically. The company reported a GAAP diluted loss per share of $6.01 due to a significant environmental liability, but adjusted diluted earnings per share reached $0.88. Strong performance in Cardiopulmonary and Neuromodulation segments, along with key regulatory milestones for the aura6000™ System, contributed to the positive quarter.
First-quarter revenue increased 7.4% reported, 8.9% constant-currency, and 10.4% organic, driven by strong demand and product rollout.
Adjusted diluted earnings per share was $0.88, demonstrating operational efficiency despite a significant environmental liability.
Completed PMA submission for the aura6000™ System and announced positive 12-month OSPREY trial data, highlighting progress in obstructive sleep apnea treatment.
Raised full-year 2025 revenue growth guidance to 6.0%-7.0% constant-currency and 7.0%-8.0% organic, reflecting stronger operational performance expectations.
LivaNova
LivaNova
LivaNova Revenue by Segment
LivaNova Revenue by Geographic Location
Revenue by Segment
Cardiopulmonary Revenue
CapyFin.comNeuromodulation Revenue
CapyFin.comOther Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comEurope Revenue
CapyFin.comRest of World Revenue
CapyFin.com Forward Guidance
LivaNova updated its full-year 2025 guidance, raising revenue growth expectations and revising adjusted diluted earnings per share to incorporate the SNIA decision and applicable tariffs, while maintaining free cash flow projections.
Positive Outlook
- Full-year 2025 revenue growth range raised to 6.0%-7.0% on a constant-currency basis (up from 5.0%-6.0%).
- Full-year 2025 organic revenue growth range raised to 7.0%-8.0% (up from 6.0%-7.0%).
- Foreign currency expected to be a smaller headwind, ranging from 0.0%-1.0% (down from 1.5%-2.0%).
- Revised adjusted diluted earnings per share range of $3.60-$3.70 incorporates stronger operational performance expectations.
- Adjusted free cash flow expected to be in the range of $135 million to $155 million, consistent with prior guidance.
Challenges Ahead
- Revised full-year 2025 adjusted diluted earnings per share range ($3.60-$3.70) now incorporates the impact of the SNIA decision.
- The SNIA decision and currently applicable tariffs are expected to reduce adjusted diluted earnings per share by approximately $0.20 in 2025.
- The company is unable to reconcile forward-looking non-GAAP financial measures to GAAP without unreasonable efforts due to unpredictable items.
- Potential impact of presently applicable tariffs is incorporated into guidance, requiring ongoing mitigation strategies.
- The SNIA environmental liability of €333.3 million ($360.4 million) was recorded, impacting GAAP diluted loss per share.
Revenue & Expenses
Visualization of income flow from segment revenue to net income